September, 19 2018
Lille (France), 19 September 2018 - ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, today announces that it has launched a study on the effect of food intake for its drug candidate AZP2006.
The dietary effect study is a randomized, single-dose crossover study to investigate the potential effects of food intake on the pharmacokinetics of AZP2006 administered orally to 14 healthy volunteers.
Previous Phase I clinical studies in 88 subjects had demonstrated that after oral administration, AZP2006 was well absorbed by the intestine and well tolerated by healthy volunteers. "This food effects study will explore the optimal timing of AZP2006 versus food intake. On the other hand, the results will make it possible to follow up on the next phase 2 clinical study in patients, planned for...
March, 26 2018
Lille (France), March 26th 2018 – ALZPROTECT, Biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, announced today the hiring of its director of pharmaceutical development.
Noëlle Callizot is an international expert in the pharmaceutical and biotech industry. For 20 years, she has enabled the pharmaceutical development of neuroactive molecules up to advanced clinical stage. As director of neuropharmacology in the UK for 6 years, she has led various programs in neurodegenerative diseases (Alzheimer's, Parkinson's, etc.). Noëlle Callizot is co-founder of 4 biotech companies in fields as varied as contract research, functional neuro-rehabilitation, screening and neuro-active molecules. President of the AFMTELETHON Pharma Commission, Ms. Callizot also chairs several strategic programs for the AFM.
Noëlle Callizot will put into...
January, 22 2018
Lille (France), January 22th, 2018 - AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of neurodegenerative diseases including Alzheimer's disease, announced 14 million euros in series B funding.
The financing round is led by Xerys who now becomes the main financial investor in the company. The company's historical investors are also participating in this funding round.
It will allow the development of the drug "AZP2006" for the treatment of Progressive Supranuclear Palsy (PSP) in Phase II clinical trials to demonstrate its effectiveness on patients. AZP2006 has the potential of becoming the first oral treatment for PSP. It is part of a group of neurodegenerative diseases that include Alzheimer's disease and Parkinson's disease.
The company’s strategy focuses on the accelerated development of AZP2006 for the treatment of PSP...